Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different doses of labetalol for bleeding control during dacryocystorhinostomy surgery
IRCT20200825048515N43Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of labetalol in dacryocystorhinostomy (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Bleeding volume, Blood pressure and 1 more. Started Oct 2021; status: completed.
02
Drugs
labetalol
03
Conditions
dacryocystorhinostomy
Beyond the preview
Go deeper on IRCT20200825048515N43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200825048515N43.